Rapid progress in the study of pancreatic somatostatin secretion has taken place, since its discovery in 1976 [65, 66, 79] . It has been shown that pancreatic D cell function is subject to a multitude of control mechanisms. This review, which deals mostly with in vitro results from mammals, will concentrate on three aspects: a) the mechanism and dynamics of pancreatic somatostatin secretion; b) the factors that influence its release; and c) secretory abnormalities of the D cell in experimental diabetes. The perfused dog pancreas preparation of Iversen and Miles [45] has turned out to be a useful and valid preparation .for this purpose.
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Methods for Studying Pancreatic Somatostatin Secretion

In Vitro Methods
The application of in vitro techniques provides a controlled environment free of the hepatic, humoral and nervous regulatory mechanisms present in vivo and makes it possible to dissect out individual factors which influence pancreatic somatostatin secretion. The isolated perfused pancreas preparation offers several advantages Over the other in vitro techniques employed: a) it allows assessment of moment-tomoment changes in secretion; b) it makes possible the collection of control and experimental data from the same pancreas; c) it has considerable functional integrity with intact circulation to the islets; d) it is exposed to minimal ~nzymatic leakage from acinar tissue which could result in impaired islet cell responses. Methods using isolated islets and monolayer cultures are deficient in these respects. A further problem arises in incubation studies where islet hormones accumulating in the medium may interfere with the normal hormone secretion.
In many perfusion methods currently used a portion of duodenum remains attached [17, 19, 20, 30, 36, 38, 64, 95] . The question has often been raised whether the endocrine cells of the duodenum may contribute to or modify the secretion of pancreatic somatostatin measured in the pancreatico-duodenal efflux thereby making interpretation of results more difficult [40, 72, 76, 77] . It has, however, been found that in the dog identical release patterns of somatostatin as well as of insulin and glucagon were obtained whether or not the duodenum was excluded during either basal or stimulated conditions [25] ( Fig. 1) .
For the evaluation of somatostatin secretion perfused pancreas preparations from dog [30, 38, 76] , pig [73] , rat [17, 19, 20, 36, 46] , and chicken [36] have been used. The perfused chicken pancreas is perhaps inappropriate if ones interest is primarily in mammalian systems since islet morphology and pancreatic hormone responses of the avian class differ distinctly from those of the mammalian e. g. insulin stimulates the pancreatic somatostatin secretion in the chicken [37] while leaving it unaffected in mammals [34, 46, 63, 67, 106] . Comparison of the secretory pattern of somatostatin from perfused dog and pig pancreas with that from perfused rat pancreas indicates that the latter is a relatively insensitive model with rather indistinct somatostatin responses to the various challenges and with basal somatostatin levels often at or below the detection limits of the assay [19, 36, 46] . It is obviously necessary to be sure that the somatostatin immunoreactivity released from the pancreas is "true" somatostatin. Validation has come from the following findings: the somatostatin like immunoreaetivity in pancreatic effluent samples shows parallelism in binding percentage with the synthetic standard on serial dilutions [8, 19, 26] , and chromatographs in a single peak corresponding to that of synthetic cyclic somatostatin [8, 19, 26] . Further support has been obtained by purification and chemical structural analysis of the extracted immunoreactive material [57, 98] .
In Vivo Methods
It is obvious that there must be reservations when trying to extrapolate in vitro findings to the in vivo state. Unfortunately the interpretation of the results of peripheral plasma somatostatin determinations in physiological and pathophysiological situations is hampered by various disadvantages. The widespread location of somatostatin secreting cells [53] implies that changes in the levels of somatostatin in the peripheral circulation may derive from variations in the release from almost anywhere. Moreover, in view of the portal-peripheral gradient [5, 86] and of the short half-life of somatostatin [71, 87, 97] it is apparent that changes in circulating somatostatin levels may bear only a slender relation to changes taking place in the pancreas. These problems can in part be circumvented by catherisation of the pancreaticoduodenal vein in large animals [84, 86, 88, 91] . Even such results cannot, however, be regarded as wholly quantitative since blood flow measurements were not performed simultaneously with blood sampling. Furthermore, the difficulty in obtaining reliable and sensitive somatostatin assays for measurements in plasma has slowed the progress of studies in intact man and animal.
Mechanism of Somatostatin Secretion
The term 'stimulus-secretion coupling' [13] has been used to cover the events occurring in a secretory cell exposed to its immediate stimulus. According to this concept calcium is regarded as a substance which couples the secretory signal to the discharge of the secretory product from endocrine cells [13] . Another potential messenger is cyclic AMP (cAMP). The question arises as to whether the effects of different modulators of pancreatic somatostatin secretion are also mediated via one or both of these second messengers. In this context the effects of cations and cyclic AMP upon somatostatin secretion are relevant to our understanding of the mechanisms of D cell secretion.
Cyclic AMP and Somatostatin Secretion
There is persuasive evidence that the release of somatostatin by the pancreatic D cell may be influenced by cyclic AMP dependent mechanisms. Barden et al. [3] first reported that high concentrations of 8-Br-cAMP stimulated somatostatin secretion from isolated islets in the presence of a normal glucose level. Agents that are supposed to increase the cellular level of the nucleotide, such as glucagon [11, 46, 63, 65, 67, 78, 79, 105, 106] ,/3-adrenergic effectors [30, 33, 76, 77] and phosphodiesterase inhibitors (theophylline) [3, 20, 63, 78] increase the somatostatin secretion. Moreover dibutyryl cyclic AMP enhances somatostatin release [63] . Some evidence suggests, however, that elevated D cell cyclic AMP concentration alone is not a sufficient stimulus to somatostatin release. Thus the very high concentration of glucagon at 5 ~tg/ml [63, 78] and 1 mmol/1 theophylline [20] were unable to cause a sustained stimulation of somatostatin release at a non-stimulatory glucose level. These findings conflict with other studies where glucagon at a low glucose [106] and theophylline in the absence of glucose [78] both elicited a modest somatostatin secretion. When evaluating the role of calcium in somatostatin secretion its relation to other cations especially the monovalent Na + and K + must be considered.
Cations and Somatostatin Release
The Role of Na § Partial replacement of extracellular Na + by choline (100mmol/1 choline, 40mmol/l Na +) provokes enhanced somatostatin secretion in the presence of extracellular calcium [24, 26] . It is possible that this somatostatin secretion is due to a cholinergic effect of the high concentration of choline, since acetylcholine has been shown to stimulate D cell secretio n [30] . The fact that the increase in somatostatin secretion which results from a decrease in extracellular Na + concentration is unaffected by the presence of 1 mmol/1 atropine seems to rule out this possibility. When extracellular calcium is omitted from the medium, the somatostatin response to a drop in extracellular Na § concentration, however, disappears [24, 26] . This points to the existence in the D cell membrane of a Na+-Ca ++ counter transport mechanism analogous to that described for other excitable tissues [6] . The somatostatin responses induced by Na + deprivation may thus be caused by an increased influx of calcium into the D cell coupled to an increased egress of Na +.
These findings emphasize the importance of extracellular Na + in somatostatin secretion. The rote of intracellular sodium has been investigated by blockade of the Na+/K + pump. This process, which increases intracellular Na + content in a wide variety of cells including pancreatic islet cells [93, 94] , stimulates somatostatin secretion [24, 32] . Thus both the addition of ouabain and the omission of extracellular K + from the medium elicit an immediate somatostatin response [24, 32] .
In addition, the alkaloid, veratridine, which increases Na + and calcium uptake through Na § channels in excitable tissue induces a biphasic somatostatin response [24, 26] . The response to veratridine is counteracted by tetrodotoxin (TTX) [24, 26] , which selectively blocks Na+-channels and thereby the inward Na + current in excitable membranes.
A clearcut distinction exists between effects obtained in the presence and in the absence of extracellular calcium. Thus no increase in somatostatin secretion occurs in the absence of calcium when veratridine [24, 26] or ouabain [24, 32] are added to the perfusate or K + is omitted [24, 32] . An increase in intracellular Na + is supposed to lead to somatostatin secretion mainly by causing a depolarization and an opening of voltage sensitive calcium channels and an increased calcium uptake into the D cell. Our findings make it unlikely, however, that an increase in intracellular Na + evokes somatostatin secretion per se or via mobilization of intracellularly bound calcium.
The Role of K +. An elevation of the potassium concentration resulted in a dose-dependent increase in the secretion of somatostatin [24, 31] . Even a small increase in K + from 4.4 to 6.9 mmol/1 results in increased somatostatin secretion (Fig. 2) . It has previously been demonstrated that a high external K + concentration induces depolarization [10] and raised calcium uptake in pancreatic islets [56] . The immediate somatostatin response to the sudden rise of external K + may therefore be the consequence of an increased calcium influx in the D cell. This is further supported by the finding that the absence of extracellular calcium abolishes somatostatin secretion in response to high K + [24, 31] .
High potassium concentrations may also cause the release of neurotransmitters from nerve terminals. The question arises therefore whether the somatostatin response to high extracellular K + is also due to neurotransmitter liberation from nerve endings in the islets. It is unlikely that acetylcholine release or catecholamine release from the parasympathetic and sympathetic nerve terminals is responsible since high concentrations of atropine [24, 31] , propranolol [24, 31] , and phentolamine ( Fig. 3) leave the potassium-induced somatostatin secretion unaffected. There is also no immunohistochemical evidence for the presence of somatostatin containing nerves in the pancreas [14] . The islets are, however, richly innervated with other peptidergic nerve fibres which contain somatostatin stimulating peptides such as CCK, VIP, and substance P [50, 52]. It cannot therefore be ruled out that such peptidergic nerves may to some degree be involved in the observed K + evoked somatostatin release.
Conclusions
The role of cyclic AMP in the control of somatostatin release may be primarily that of a modulator without being an essential factor for initiation of somatostatin release. Much work is, however, still required to elucidate the exact nature of the role of cyclic AMP in the secretory mechanism of the D cell. All of the present evidence, however, points to a key regulatory role for calcium in the cascade of events that proceeds to the somatostatin secretion [24, 26, [30] [31] [32] [33] . The data indicate that the changes in somatostatin secretion provoked by alterations in the extra-and intracellular levels of Na + and K + are secondary to changes in the intracellular level of calcium in the D cell. Caution should, however, be exercised in deducing from the results from cation fluxes in whole islets because of the mixed cell population studied. They cannot be assumed to represent the responses of the D cell alone because these cells make up only 5-15% of the total cell mass in the islet.
Dynamics of Somatostatin Secretion
The secretory characteristics of somatostatin release have much in common with those of insulin release. Thus in the isolated perfused dog pancreas a square wave pulse of high glucose induces a biphasic increase in the secretion of somatostatin [27, 29, 36, 105] . It consists of a peak release starting 1-2 min after the glucose challenge (First phase); after about 5 rain this is followed by a lesser more prolonged secretion (Second phase). Although one group has reported to the contrary [81, 82] , the omission of glucose results in an immediate decline in somatostatin release [17, 29, 36, 38, 105] .
The dynamics of the somatostatin release are concentration-dependent. Low concentrations of glucose thus merely elicit a transient burst of secretory activity, and the biphasic nature of the secretory response manifests itself only as the glucose level is increased [29] . Biphasic profiles of somatostatin secretion are also obtained with high concentrations of agents such as arginine [19, 20, 30, 106] The underlying mechanism responsible for the biphasic somatostatin response is obviously of interest. It may be due to the existence of two pools of somatostatin analogous to the proposals for the pancreatic B cell [9, 69] . Another suggestion is that somatostatin released during the first phase inhibits subsequent secretion. Thus Ipp et al. [43] have demonstrated an inhibitory effect of somatostatin on somatostatin secretion by the dog pancreas.
Recently, Stagner et al. [99] made the interesting observation in the perfused dog pancreas of regular, sustained oscillations of somatostatin with a 10 minute period. The monophasic cycle curves in vitro were not produced by adrenergic or cholinergic mechanisms and were not a result of glucose changes [99] . The drive may come from spontaneous firing of peptidergic nerves in pancreas [50, 52] . By considering the pancreatic D cell as a neuroendocrine cell [68] spontaneous activity in the D cell itself becomes another possibility. The nature of the pacemaker that serves to drive islet cycles is, however, not known.
Factors Modifying Normal Pancreatic Somatostatin Secretion
Carbohydrates Glucose stimulates somatostatin secretion in vitro [17, 19, 27, 29, 33, 38, 63, 79, 105] although one group of investigators were not able to demonstrate any increase in somatostatin release from incubated rat islets [3] . Increased perfusate glucose also markedly enhances the somatostatin response to agents such as calcium [24, 30] , and substance P [27] . A sigmoidal curve characterizes the relationship between the glucose concentration of the extracellular medium and the rate at which somatostatin is released [29] . The D cell threshold for glucose is close to 5 mmol/1 in the isolated dog pancreas [28, 29, 38] and to 10 mmol/1 in incubated rat pancreatic islets [19, 78] . In the dog half maximal release occurs between 5 and 10 mmol/1 and maximal release is reached at about 20 mmol/1 [28, 29] . The steep portion of the dose-response curve for somatostatin release from the dog pancreas [29] corresponds to the range of glucose found in the blood postprandially, which suggests a possible physiological role for the glucose-induced somatostatin release.
How the pancreatic D cell recognizes and responds to glucose is unknown. In analogy with the suggested models for the B cell glucoreceptor [10, 49, 70] at least three explanations can be offered. Somatostatin release may be triggered by the intact glucose molecule itself or it may be that the metabolism of glucose within the D cell provides intracellular signals which initiate somatostatin secretion; finally the two models may function simultaneously. Several lines of evidence seem to indicate that the Secondly, mannoheptulose, which markedly inhibits islet glucose metabolism but not that of Dglyceraldehyde, dramatically inhibits glucose stimulated somatostatin secretion [28, 29, 79, 83] while it has no effect on the D cell response to D-glyceraldehyde [28, 29] .
Thirdly, the D cell secretion is unaffected by nonor poorly metabolized sugars such as ribose [29] , fructose [29] , and galactose [29, 63] .
Non-carbohydrate Nutrients
Arginine [17, 19, 20, 30, 33, 63, 66] , leucine [38, 78] , a 10 amino acid mixture [38] and the amino-acid metabolite a-ketoisocaproic acid [78] are all powerful stimulators of somatostatin secretion. The implications of the finding that a-ketoisocaproic acidstimulated D cell secretion is inhibited by epinephrine [83] but not by mannoheptulose [83] is uncertain.
The ketone body 3-hydroxybutyrate also augments somatostatin secretion by the isolated dog pancreas (Fig. 4) . In this context it is interesting to note that heparin and intralipid in vivo cause a clearcut increase in circulating somatostatin levels [104] . The increase may be attributed to either free fatty acids or to ketone bodies.
Effects of Pancreatic Islet and Gut Hormones
It is apparent from in vivo studies [86, 90] The question whether somatostatin exerts a direct inhibitory action on its own secretion is of obvious importance since such a feed-back mechanism may contribute to the biphasic nature of the somatostatin response to various agents. Two Smaller molecular forms of CCK also stimulate D cell hormone secretion. Thus CCK-3, CCK-4, and CCK-5 at doses ranging between 10 -7 to 10 -3 mmol/1 cause a dose-related somatostatin secretion from the isolated porcine pancreas [73] . CCK-4 is far the most potent of these peptides [73] .
Somatostatin secretion is also stimulated by vasoactive intestinal polypeptide (VIP) [27, 41] and substance P [27], both of which are found in neurones in the pancreas [50, 52] . It is unknown whether the stimulant action on the D cell is aided by a vasodilator effect on islet capillaries. Our results are consistent with the view that substance P even at concentrations which can be delivered to the pancreatic islet cells by the circulation stimulates the secretion of somatostatin in a dose-related manner [27] .
In contrast bombesin, a newly recognized tetradecapeptide contained in endocrine ceils in duodenum, has no effect on somatostatin secretion [27] . The reported effects of neurotensin are, however, puzzling. Dolais-Kitabgi [11, 12] found that 100nmol/1 neurotensin stimulated somatostatin release at low glucose (3 mmol/1), that it did not alter somatostatin secretion in response to high glucose (12 mmol/1) and glucagon (2 ~tg/ml) and indeed inhibited D cell secretion during stimulation with very high glucose (23 mmol/1) or arginine (20 mmol/1) concentrations. Since the D cells of their preparation of isolated islets are unresponsive to variation in glucose from 3 to 23 mmol/1 and to addition of 2 ~tg/ml glucagon [11, 12] the results must be viewed cautiously.
The demonstration of immunoreactive enkephalin in pancreas [50] points to a possible regulatory role of this opioid on islet cell function. Ipp et al. [42] have reported that another endogenous opioid, /3-endorphin, and the exogenous opiate, morphine sulphate, exert inhibitory effects on somatostatin secretion, which could be abolished by the antagonist naloxone hydrochloride. Whether locally secreted enkephalin influences such hypothetically opiate receptors in the islets is, however, unknown.
The physiological meaning of the observations of peptide-induced alteration in D cell secretion is still obscure since no data are avaiable on the concentration of the peptides surrounding the islet cells in different physiological conditions.
Nervous Control of Pancreatic Somatostatin Secretion
In most mammals three main types of nerves have been demonstrated in the pancreas: adrenergic, cholinergic and peptidergic [50, 52] .
Using the isolated dog pancreas, Samols et al. have shown that a-adrenergic stimulation inhibited somatostatin secretion [76, 77] , a conclusion that is supported by the results of Ipp et al. [39] . Furthermore, Samols et al. [76, 77] showed that the /3-adrenergic effects of epinephrine and isoproterenol were to enhance somatostatin secretion. Our studies confirm this latter finding [30, 33] . The administration of epinephrine alone, at doses of 2 ~tg/ml and 10ng/ml, respectively, elicits an inhibition in somatostatin release from rat islets [79, 83] and dog pancreas [39] . Using the smaller epinephrine dose of 2 ng/ml Samols et al. [76, 77] , however, could find no significant change in somatostatin secretion. Dopamine, which is present in pancreatic islets in high concentrations [107] has also been shown to alter somatostatin secretion. Dopamine (10-4mmol/1) inhibits somatostatin release, an action which can be prevented by the dopaminergic antagonist (+) butaclamol (5 • 10 -5 mmol/1) [4] . It is not known if dopamine is a neurotransmitter in the pancreas, and the significance of these findings remain therefore to be elucidated, but a role for other adrenergic agents seems possible.
Acetylcholine, the transmitter of the parasympathetic nervous system, exerts only a minor and variable effect on hormone secretion from D cells as compared to the action on the A, B, and PP cell secretion [35] . Samols et al. [77] reported a mild suppressive effect of 10 ~tmol/1 acetylcholine on somatostatin secretion. In contrast we found a modest stimulation of somatostatin release by 1 ~tmol/1 acetylcholine [30, 33] . By using another source of acetylcholine [35], we, however, were unable to demonstrate any effect on the somatostatin release. A significant point in this context may be that there is large interindividual differences between pancreases in the sensitivity of the D cells to acetylcholine. Thus current experiments with the more stable carbamylcholine chloride demonstrate that while a definite dose-related stimulation of somatostatin release is obtained in some pancreata, others are refractory (K. Hermansen, unpublished observations). The reason for this puzzling phenomenon is unknown, but it seems that cholinergic mechanisms play no major regulatory role in pancreatic D cell secretion.
Peptidergic nerves are also found in the pancreas. They can release substance P, VIP, enkephalin, and gastrin/CCK [50, 52]. The effects of these peptides on the pancreatic somatostatin secretion have already been described. No somatostatin containing nerves are, however, present within the pancreas [14] i. e. the somatostatin measured in the efflux from islets or the entire pancreas derives exclusively from endocrine cells. The fact that certain of the effects on pancreatic hormone secretion induced by pancreatic nerve stimulation cannot be prevented by adrenergic or cholinergic blockade, strongly suggests an important regulatory role of the peptidergic nerves.
In conclusion, the rates at which somatostatin is released from the pancreas is now known to be modified by the autonomic innervation. However, the evidence is as yet fragmentary and the extent to which neural mechanisms may be integrated in the production of the somatostatin responses to physiological stimuli certainly needs further exploration.
Somatostatin Release in Response to Pharmacological Agents
Ipp et al. [38] have demonstrated that tolbutamide in the presence of 5.5mmol/1 glucose stimulates somatostatin secretion. Similarly Samols et al. [74] found a stimulatory effect of tolbutamide (130 ~tmol/1) on D cell secretion, greater, however, at low (0.8 mmol/1) than at normal glucose levels (4.9 mmol/1). The somatostatin response to the sulfonurea, glibenclamide, was also found to be lowest at high glucose concentrations [15] . Furthermore, glibenclamide (1 ~tg/ml) significantly enhanced the effect of arginine on somatostatin release [16] . In contrast, the hyperglycemic sulfonamide, diazoxide (130~tmol/1) inhibits somatostatin secretion [77] . With respect to the effects of sulphonylureas, there is thus again a striking similarity between D and B cell responses.
Functional Role of Pancreatic Somatostatin
Local Role?
The presence in pancreatic islets of D cells in juxtaposition to the B and in particular the A cells had led to the postulate of a local regulatory role for somatostatin on the pancreatic release of glucagon and insulin, that is a paracrine function of the D cell [61] . The facts that the pancreatic D cells secrete somatostatin and that islet cells can be influenced by the secretory products of other islet cells make this an attractive possibility. The assertion of Larsson et al. One approach to answer the question about direct within-islet actions has been the attempt to neutralize pancreatic hormones with antibodies. In vivo, administration of anti-somatostatin serum left both basal and stimulated glucagon and insulin levels unchanged, although plasma growth hormone levels rose [1, 89, 102] . Similarly, active immunization resulted in an increase of serum growth hormone levels, but did not affect basal and stimulated secretion of glucagon [100] . This has been interpreted as indicating that any influence of endogenous somatostatin on hormone secretion from the A and B cells takes place via a pathway inaccessible to the blood borne antisomatostatin serum [1, 89] . The dissociation of the effects of antisomatostatin serum on islet hormones and growth hormone levels may, however, reflect a differential sensitivity to somatostatin. Thus insufficient somatostatin antibody may have been administered to neutralize enough somatostatin to alter insulin and glucagon secretion. Higher concentrations of islet hormone antibodies can, however, be obtained in the vicinity of the islet cells when antibodies are applied to isolated islets. Using this technique Taniguchi et al. [101] found that insulin secretion was increased at low (3.3 mmol/1) and moderate (8.3 mmol/1) glucose levels, while it was unchanged at high glucose (16.7mmol/1). In contrast, Barden et al. [4] found no elevation of insulin secretion at a normal glucose level (5.5 mmol/1) whereas a marked increase in glucagon release appeared following neutralization of endogenous somatostatin. Antiglucagon serum has also been shown to produce a small decrease in basal secretion of somatostatin from rat islets whereas attempts to neutralize insulin leave somatostatin release unaffected [63] . It has been suggested that if neutralisation of an islet hormone alters the release of one of the other islet hormones this favours the existence of a paracrine system of secretory control within the pancreatic islets [1, 63] . This is, however, not necessarily correct since it remains probable that the detected changes in release of islet hormones are due solely to neutralisation of the hormone stored between and not within islets.
Other anatomical features could also be relevant to a local role for somatostatin. The local portal vessel system in the islets [18] may allow secreted somatostatin to act on islet cells within the same islet. Although local such a mechanism should be considered as endocrine.
The qualitative heterogeneity of the responses of A, B, and D cells to different agents seems, however, difficult to interpret in terms of intra-islet feed-back mechanisms. The development of specific D cell agonists or antagonists may help to gain further insight to this problem.
Endocrine Role?
In addition to potential actions within the islets several lines of evidence point to an extra-isletendocrine role for pancreatic somatostatin. First of all, pancreatic somatostatin secretion is stimulated by nutrients and gastrointestinal hormones both in vivo [74, 86, 88] and in vitro [4, 17, 19, 27, 30, 33, 38, 40, 63, 65, 66, 79, 105, 106] . Also, in the peripheral circulation variations in the somatostatin level can be seen in response to physiological stimuli.
Secondly, biological actions can be produced by physiological increments in the somatostatin level. The intraportal infusion of synthetic somatostatin at a rate which induces a physiological rise in peripheral somatostatin is associated with a significant decrease in the rate of entry of nutrients from the gut into the circulation [85] . Moreover, inhibition of insulin and glucagon secretion from the isolated dog pancreas is elicited by somatostatin concentrations which can easily be achieved in the periphery in vivo in response to various physiological stimuli [35] . Although somatostatin has a short half-life [71, 87] and despite the difficulties in adressing the multiple actions of somatostatin on endocrine and exocrine functions (for reviews see [22, 53] ) substantial evidence indicates that the action of this peptide extends beyond those of a potential paracrine nature.
In addition to regulating nutrient influx from the gastrointestinal tract, somatostatin may have other actions which contribute to nutrient homeostasis. Thus it may affect glucose metabolism by directly or indirectly altering hepatic glucose output (for review see [55] ), glucose disposal to tissues [44] or central nervous system actions on glucoregulation [7] . At present, a cybernetic system with pancreatic somatostatin acting as a regulatory messenger in the gastroenteroinsular axis seems possible. In response to ingestion of nutrients, the gastrointestinal hormones, the gastrointestinal nervous system and the absorbed substrates may determine the secretory rate of pancreatic somatostatin which in turn acts as modulator of the secretion of gastrointestinal hormones (for review see [22, 53] ), of neuronal function (for review see [53] ), and of substrate absorption [85, 92, 103] .
Fasting and D Cell Function
Fasting results in a decrease in portal somatostatin level in rats [47, 96] indicating a decreased secretory activity of pancreatic D cells during fasting. These two studies are not consistent with the in vitro results of Schauder et al. [80] which showed that islets from fasted rats release significantly more somatostatin than controls in the presence of 3.3 mmol/1 glucose, whereas the release at 10 or 25 mmol/l glucose was in the normal range. However, basal somatostatin secretion from the perfused rat pancreas is attenuated [95] . Of interest is the finding that in the fasted state somatostatin release is apparently independent of the prevailing glucose concentration (3.3, 10 or 25 mmol/1) [80] suggesting that the fasted islet D cells have at least temporarily lost their ability to recognize glucose, whereas they still respond to arginine [95] .
Diabetes and D Cell Function
The observations of both an increase in the islet and pancreatic contents of somatostatin [58, 64] , of an augmentation of D cell number [59] and of increased plasma somatostatin levels in insulin-deficient diabetes [47, 84] has raised the possibility that abnormalities in pancreatic somatostatin secretion may be present in diabetes. This suggestion is supported in a recent report of Schusdziarra et al. [90] demonstrating that the variations in peripheral plasma somatostatin levels in alloxan diabetic dogs differed from those of normal dogs. In the experimental diabetic dogs the rise in plasma somatostatin levels to a protein rich meal is delayed, but surpasses that seen in normals [90] . The postprandial as well as the fasting plasma somatostatin levels were unchanged in normals [90] while they were diminished although not to normal, in the diabetic dogs during insulin administration [90] . In contrast to what is seen in normal dogs no significant change in plasma comatostatin level appeared in response to orally or parenterally administered glucose [90] .
We have also found that neither somatostatin nor glucagon secretion from the isolated pancreas of streptozotocin diabetic dogs altered in response to variations in perfusate glucose, manoeuvres which in pancreata from normal animals are invariably accompanied by swift but opposite changes in hormone release from the D and A cells [34] . In contrast other substances such as arginine, the fl-adrenergic agonist isoproterenol, calcium, and glucagon (Fig. 5) , all stimulated the release of somatostatin from the diabetic pancreas [34] as in the normal pancreas. Hara et al. [22] found that both basal and arginine stimulated somatostatin release from perfused pancreas of alloxan diabetic rats were approximately twofold increased as compared to normals, whereas the glucagon levels were decreased.
It is not clear whether the D and A cell abnormalities described [34] are secondary to insulin deficiency. However, the finding that insulin treatment in The diversity between in vivo [90] and in vitro results [34] concerning the effect of insulin on the somatostatin level in diabetes remains unexplained. However, similar secretory characteristics exist for glucagon. It could be speculated that the increased somatostatin levels in acute experimental diabetes [47, 84, 90] were at least partly induced by either increased concentrations of ketone bodies or high glucagon levels, the latter being able to augment somatostatin secretion from the isolated pancreas of streptozocin diabetic dogs (Fig. 5) .
A possible explanation is that experimental diabetes might be an overall islet cell disease due to a common, rather selective dysfunction of the glucoreceptor, which in this context includes both models: the regulator site and the substrate site models [70] . The metabolic abnormalities characterizing the diabetic state may be caused by a dysfunction of D as well as of A and B cells in the pancreas (or possibly of all cells?) [34] .
To explore the molecular basis of the D cell impairement in experimental diabetes we have investigated the influence of various carbohydrates on somatostatin secretion in vitro and compared them with the normal responses [28] . The glucose metabolites D-glyceraldehyde (1.25 and 2.5 mmol/1) and dihydroxyacetone (11 mmol/l) which normally stimulate somatostatin secretion do not augment somatostatin secretion from the perfused pancreas of streptozotocin diabetic dogs [28] . Although D-glyceraldehyde at high doses causes an inhibition of somatostatin secretion in normal [28, 29, 54, 78] as well as in diabetic pancreas [28] this may well be due to nonspecific effects through ATP depletion [2] . In addition mannoheptulose (5 mmol/1) has no effect on somatostatin secretion from the diabetic dog pancreas [28] . Thus the diabetic D cell has lost its ability to respond to glucose and its metabolites. Whether the D cell abnormalities are caused by a direct action of streptozotocin, by longstanding insulin deficiency in the vicinity of the D cell or are secondary to alterations in intermediary metabolism remains to be solved.
If one physiological function of pancreatic somatostatin is to restrain nutrient entry from gut as suggested by Unger et al. [92, 95, 103] it could be expected that abnormalities in pancreatic somatostatin secretion would also contribute to the metabolic derangement in experimental diabetes. If the normal increase in plasma somatostatin to glucose is extinct, one would predict, that the negative feed-back control over the rate of glucose entry should disappear. This would result in a more rapid entry of glucose and an augmentation of the arterial concentration of glucose. The absent increase in somatostatin secretion to glucose may further indirectly contribute to the metabolic abnormalities in diabetes due to the potential loss of glucagon suppression thereby allowing enhanced heptatic glucose production and ketogenesis. On the other hand the hypersomatostatinaemia in insulinopenic diabetes may reflect a futile compensatory effort to correct the hyperglycaemia.
Although still at an early stage studies on D cell function in normal and diabetic animal models seem to be a fertile field. The results indicate that much can be learned from such studies and with respect to diabetes it may prove fruitful to use other experimental models. 
